Gemcitabine Bladder Instillation Syringe


Gemcitabine Bladder Instillation


Edge Pharma offers compounded Gemcitabine Bladder Instillation Syringe kits that include a 1g / 50mL pre-filled unit-dose syringe of Gemcitabine, a closed system transfer device (CSTD), and catheter tip. The CSTD is attached by Edge in an ISO 5 environment according to cGMP. This solution helps solve the USP 800 hazardous compounding challenge many hospitals and clinics now face when trying to administer Gemcitabine. Since the product comes ready-to-administer, you do not need to compound a hazardous drug in your facility. Edge specializes in offering hazardous compounding services for organizations, making the transition to USP 800 compliance easier.


Gemcitabine Bladder Instillation Kit

Gemcitabine intravesical solution, sterile, preservative free.

Available Dosage = 1 g
Syringe Volume = 50 mL
Closed system transfer device (CSTD) and catheter tip included with kit.


Literature Review

A landmark national study, with 23 cancer centers participating, showed Gemcitabine’s great promise. The study was led by the Wilmot Cancer Institute at the University of Rochester. For the study, patients had their bladder tumor removed and immediately, post-surgery, were administered Gemcitabine through a catheter, directly into the bladder area.(1) The study showed a 34 percent reduction in cancer recurrence.(2)

Most bladder cancers – seven out of 10 cases – are diagnosed at an early stage when they are highly treatable, according to the Mayo Clinic. But even when treated, bladder cancer often recurs. “For this reason, people with bladder cancer typically need follow-up tests for years after treatment to look for bladder cancer that recurs or advances to a higher stage.”(3)

Each year in the U.S., some 56,000 men and 18,000 women are diagnosed with bladder cancer, according to the Centers for Disease Control.(4) Bladder cancer is the fourth most common cancer found in men in the U.S. – the chance a man will develop bladder cancer during his lifetime is about one in 27; the rate for women is about one in 89.(5)

(1) Wilmot Cancer Institute, University of Rochester, online article, Investigators Looking to a Better Future for Patients with Bladder Cancer
(2) Journal of the American Medical Association, online article, Effect of Intravesical Instillation of Gemcitabine vs. Saline Immediately following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence
(3) Mayo Clinic, online article, Bladder Cancer: Symptoms and Causes
(4) Centers for Disease Control and Prevention, online article, Bladder Cancer
(5) American Cancer Society, online article, Key Statistics for Bladder Cancer

Register To Order Online 

We are currently licensed to sell to all US states except Alabama and Virginia. Please fill the form below to create an account. Medical, DEA, or hospital pharmacy licenses will be required to order gemcitabine.

Create an account to order

Log-In if you have an account